Licensed Investment Opportunity
Thirty years of clinical protocols and proven outcomes, deployed into infrastructure you already own across four locations. A turnkey program built for recurring, high-margin revenue.
Prepared by Dr. Thomas A. Santucci, DC, CNS, AFNI · NeuroIntegrative Care · Confidential — June 2026
This isn’t a bet on an emerging trend. The demand is here, the buyers are affluent, and your facilities are already standing.
The global longevity and regenerative-health market is on track to exceed $600 billion by 2030, driven by affluent consumers actively seeking science-backed, results-oriented wellness. Premium health corridors and high-net-worth populations represent two of the most receptive markets on earth for this category.
Six clinically validated niches, deployable inside your existing operations. You are not creating a market — you are capturing one.
Most healthcare ventures fail on the time, capital, and expertise needed to build reliable clinical and operational infrastructure. That work is finished.
30 years of clinical refinement, real-world outcomes, and operational iteration — already absorbed into documented protocols. Closer to acquiring a franchise with a track record than launching a startup.
No new build-out, no R&D, nothing to invent. You receive a tested, outcomes-proven engine with a defined path to profitability from day one.
Your facilities already carry the fixed costs — lease, staff, utilities. The program activates underused capacity into a high-margin revenue stream. Incremental revenue on a sunk-cost base.
Six niche offerings, advanced therapies, and a five-tier patient journey built to move patients deeper into care over time.
Patients who see measurable gains in cognition, energy, weight, or inflammatory markers don’t stop — they invest more. Each year’s retained cohort becomes the floor on which new-patient revenue is built. By Year 3, a significant share of revenue comes from patients acquired in Years 1 and 2 — with no additional acquisition cost.
Protocols alone can be copied. The defensible advantage is the operating system that delivers them — consistently, at fidelity, by trainable staff, across every location.
Each individual procedure in the program is available to the wider market. What is not replicable is how they are assembled and delivered — and that logic lives inside the operating system. Building it as one custom platform, rather than stitching together generic spa tools, is what turns a great practice into a licensable, scalable asset:
The OS encodes the clinical decision logic, so trainable staff deliver Dr. Santucci-level consistency — without requiring his credentials in every chair.
Disparate clinical, admin, and patient-management functions run in one framework, cutting duplicated systems and headcount and making staff interchangeable across roles.
Open the next clinic on the same rails — protocols, training, patient journey, and reporting are switched on, not rebuilt.
The value isn’t a binder of procedures anyone can copy — it’s the proprietary system that operates them, owned centrally and licensed to you.
Year 1 ramps over four quarters; Years 2–4 stabilize as fixed costs are absorbed and recurring revenue builds. All figures are pre-approval working projections.
| Quarter | Q1 | Q2 | Q3 | Q4 | Year 1 |
|---|---|---|---|---|---|
| Revenue / location | $350,000 | $450,000 | $550,000 | $650,000 | $2,000,000 |
$2.0M per location in Year 1 · $8.0M aggregated across four locations.
| Year | Total Revenue | Net Profit | Cumulative ROI |
|---|---|---|---|
| Year 1 | $8.0M | $1.3M | 0.4X |
| Year 2 | $8M–$14M | $4.4M–$6.7M | 1.3X–1.8X |
| Year 3 | $8M–$14M | $4.4M–$6.7M | 2.2X–3.2X |
| Year 4 | $8M–$14M | $4.4M–$6.7M | 3.1X–4.5X |
| 4-Year Total | $38M–$50M | $14.9M–$21.8M | 3.1X–4.5X |
Key assumptions: 25% COGS · operating expenses at 50% of prior baseline ($1.664M) · 7% royalty · 15% est. tax. Conservative-to-moderate range; payback ~18 months.
| Category | Conservative | Moderate | Basis |
|---|---|---|---|
| Gross Revenue | $14,000,000 | $14,000,000 | Therapies + peptides at full utilization |
| Cost of Goods Sold | $2,500,000 | $3,500,000 | 25% — consumables, labs, supplements |
| Gross Profit | $7,500,000 | $10,500,000 | 75% margin |
| Operating Expenses | $1,664,000 | $1,664,000 | 50% of baseline — leveraged from existing spa |
| EBITDA | $8,836,000 | $8,836,000 | |
| Royalty (7%) | $980,000 | $980,000 | To Licensor |
| Operating Profit (EBIT) | $7,856,000 | $7,856,000 | |
| Taxes (est. 15%) | $1,178,400 | $1,178,400 | |
| Net Profit | $6,678,000 | $6,678,000 |
Operating expenses comprise marketing $300K · staffing $840K · facility $224K · tech & systems $168K · compliance $132K. Working figures pending final review.
The bundled multi-unit rate rewards commitment to scale; a single-location license would carry a higher per-unit cost. The $1M Year-1 tranche aligns payment timing with demonstrated revenue.
A $600B category by 2030 with affluent, motivated buyers in the markets you already operate. Demand exists today.
30 years of refinement already absorbed. You acquire a proven engine, not a science project — closer to a franchise than a startup.
Incremental revenue on a sunk-cost base. Every patient above breakeven flows almost entirely to the bottom line.
The 5-tier journey moves patients deeper over time. Retained cohorts become the revenue floor — without new acquisition cost.
20 patients/day at $300 is a fraction of capacity; premium programs run $400–$600/visit. Pricing and volume upside falls straight to net profit.
Dr. Santucci and the advisory board stay structurally engaged — quarterly reviews on EMR data, with enhanced support if targets are missed.
Clinical depth, product commercialization, and international distribution — engaged throughout the agreement.
Founder of NeuroIntegrative Care of Los Gatos. 30+ years in functional neurology, neurometabolic science, and regenerative medicine — integrating qEEG brain mapping, neurotransmitter panels, genomic profiling, and targeted regenerative protocols. Provides clinical leadership, licensing, and the protocol IP at the core of the program.
Leads a Silicon Valley product design and development firm with DNA from Apple and Stanford’s Product Design program. Bridges clinical excellence with commercial scalability — AI-driven systems, healthtech, and the operating system that makes the model licensable and repeatable.
Deep experience in high-volume distribution, strategic accounts, and scalable operations. Guides cross-border partnership and B2B go-to-market for multi-site hospital and longevity programs.
Confirm territory and terms; execute the license. $3M at signing.
Stand up the platform on your infrastructure; configure protocols and the patient journey.
Staff training (Zoom + video + on-site); deploy laser/PEMF equipment.
Go live; quarterly EMR-based reviews steer the Year-1 ramp to $2M/location.
A working session to confirm territory, finalize terms, and lock the launch timeline. You are not being asked to build something from scratch — you are deploying a proven, documented system into infrastructure you already own.